Acknowledgement to Referees.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1029, doi. 10.1007/s40262-013-0116-z
- Publication type:
- Article
Works matching IS 03125963 AND DT 2013 AND VI 52 AND IP 12
Results: 9
1
2
Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.
- Published in:
- 2013
- By:
- Publication type:
- journal article
3
Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1111, doi. 10.1007/s40262-013-0092-3
- By:
- Publication type:
- Article
4
Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1127, doi. 10.1007/s40262-013-0101-6
- By:
- Publication type:
- Article
5
Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1063, doi. 10.1007/s40262-013-0098-x
- By:
- Publication type:
- Article
6
Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1045, doi. 10.1007/s40262-013-0088-z
- By:
- Publication type:
- Article
7
Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1101, doi. 10.1007/s40262-013-0091-4
- By:
- Publication type:
- Article
8
Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1085, doi. 10.1007/s40262-013-0089-y
- By:
- Publication type:
- Article
9
Random-Effects Linear Modeling and Sample Size Tables for Two Special Crossover Designs of Average Bioequivalence Studies: The Four-Period, Two-Sequence, Two-Formulation and Six-Period, Three-Sequence, Three-Formulation Designs.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 12, p. 1033, doi. 10.1007/s40262-013-0103-4
- By:
- Publication type:
- Article